Recent 8-K filings for ZBH

• May 12, 2026, 6:30 AM ET other material materiality 0.75 positive item 7.01item 5.02item 9.01

  Zimmer Biomet increases FY2026 share repurchase target to $1B, up $250M from prior view

  Now expects to repurchase up to $1.0B of common stock in FY2026, a $250M increase from prior assumption.

• April 28, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  ZBH Q1 net sales $2.09B (+9.3% reported); adj EPS $2.09 (+15.5%); raises FY adj EPS guidance to $8.40-$8.55

  Q1 net sales $2.087B, +9.3% reported, +6.8% constant currency, +2.9% organic constant currency.

• April 28, 2026, 7:59 PM ET leadership materiality 0.65 neutral item 5.02item 7.01item 9.01 ◈ executive_change ×2

  Zimmer Biomet CFO Suketu Upadhyay resigns; Paul Stellato named interim CFO

  Suketu Upadhyay resigns as CFO and EVP effective April 28, 2026, to pursue a new opportunity.

• October 7, 2025, 7:59 PM ET M&A materiality 0.85 positive item 8.01item 9.01

  Zimmer Biomet completes acquisition of Monogram Technologies for $4.04/sh plus CVRs up to $12.37

  Each Monogram common share converted to $4.04 cash and non-tradeable CVRs worth up to $12.37 upon milestone achievement.

• September 4, 2025, 7:59 PM ET debt materiality 0.60 neutral item 8.01

  Zimmer Biomet issues CHF 600M in two tranches of senior unsecured bonds due 2030 and 2035

  CHF 210M 0.930% bonds due Sept 4, 2030 (Tranche A) and CHF 390M 1.560% bonds due Sept 4, 2035 (Tranche B) issued.

• July 14, 2025, 7:59 PM ET M&A materiality 0.70 positive item 7.01item 8.01item 9.01

  Zimmer Biomet to acquire Monogram Technologies for ~$177M upfront plus CVR up to $12.37/share

  Equity value ~$177M ($4.04/share cash upfront); enterprise value ~$168M.

• May 5, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Zimmer Biomet Q1 rev +1.1%; guides 2025 adj EPS down to $7.90-$8.10, rev up including Paragon 28

  Q1 net sales $1.909B (+1.1% reported, +2.3% CC); GAAP EPS $0.91, adjusted EPS $1.81.

• April 21, 2025, 7:59 PM ET M&A materiality 0.75 positive item 8.01item 9.01

  Zimmer Biomet completes acquisition of Paragon 28 for $13.00/share plus CVR

  Closing on April 21, 2025; each Paragon 28 share converted to $13.00 cash plus up to $1.00 CVR tied to revenue milestones.

• February 19, 2025, 6:59 PM ET debt materiality 0.75 neutral item 1.01item 2.03item 9.01 ◈ Debt Financings ×3

  Zimmer Biomet issues $1.75B in three tranches of notes; special redemption tied to Paragon 28 merger

  Issued $600M 4.700% notes due 2027, $550M 5.050% notes due 2030, and $600M 5.500% notes due 2035.

• February 18, 2025, 6:59 PM ET debt materiality 0.60 neutral item 1.01item 9.01

  Zimmer Biomet issues $1.75B in notes at 4.700%, 5.050%, and 5.500%

  Offering includes $600M 4.700% notes due 2027, $550M 5.050% notes due 2030, and $600M 5.500% notes due 2035.

• February 6, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Zimmer Biomet Q4 sales $2.02B (+4.9% CC), adj. EPS $2.31; guides FY2025 adj. EPS $8.15-$8.35

  Q4 net sales $2.023B (+4.9% constant currency); Q4 adjusted diluted EPS $2.31.

• January 29, 2025, 6:59 PM ET M&A materiality 0.80 positive item 7.01item 9.01

  Zimmer Biomet to acquire Paragon 28 for $1.2B enterprise value, $13/share cash plus CVR

  Upfront $13.00 per share cash (~$1.1B equity); CVR up to $1.00/share if FY2026 net sales exceed $346M.

• January 29, 2025, 6:59 PM ET M&A materiality 0.85 positive item 1.01item 9.01

  Zimmer Biomet to acquire Paragon 28 for $13.00 per share cash plus up to $1.00 CVR

  Deal consideration: $13.00 per share cash plus Contingent Value Right (CVR) with max $1.00 payable if Paragon 28 net revenue exceeds $361M in 2026.

• November 20, 2024, 6:59 PM ET debt materiality 0.60 neutral item 1.01item 2.03item 9.01

  Zimmer Biomet issues €700M of 3.518% notes due 2032

  €700M aggregate principal, 3.518% annual interest, matures Dec 15, 2032.

• November 19, 2024, 6:59 PM ET debt materiality 0.60 neutral item 1.01item 9.01

  Zimmer Biomet prices €700M 3.518% notes due 2032; proceeds to repay 2024 notes

  Issued €700M aggregate principal of 3.518% notes due December 15, 2032.

• October 30, 2024, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  Zimmer Biomet Q3 sales up 4.1% cc; lowers FY2024 guidance

  Q3 net sales $1.824B (+4.1% cc); diluted EPS $1.23, adjusted EPS $1.74.

• August 7, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Zimmer Biomet Q2 adjusted EPS $2.01 beats; revenue +5.6% CC; full-year guidance reaffirmed

  Q2 net sales $1.942B (+5.6% constant currency); diluted EPS $1.18 GAAP, $2.01 adjusted, exceeding expectations.

• May 2, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Zimmer Biomet Q1 net sales $1.889B (+3.2%); adj. EPS $1.94; reiterates FY guidance

  Net sales $1.889B, up 3.2% reported and 4.4% constant currency; GAAP diluted EPS $0.84, adjusted $1.94.

• February 8, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Zimmer Biomet Q4 2023 net sales $1.94B (+6.3%), adj EPS $2.20; guides FY24 adj EPS $8.00-$8.15

  Q4 net sales $1.94B (+6.3% reported, +6.1% CC); diluted EPS $2.01, adjusted $2.20.

• August 22, 2023, 7:59 PM ET leadership materiality 0.75 neutral item 5.02item 7.01item 9.01 ◈ executive_change ×5

  Zimmer Biomet appoints Ivan Tornos as CEO, Christopher Begley as Chairman; Suketu Upadhyay expands role

  Bryan Hanson steps down as Chairman, President & CEO effective Aug 22, 2023; remains advisory through Aug 31.

• May 2, 2023, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Zimmer Biomet Q1 net sales $1.831B (+10.1% reported, +13.2% CC); raises FY2023 guidance

  Q1 diluted EPS $1.11 GAAP, adjusted $1.89; net earnings $232.5M GAAP, $396.8M adjusted.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.53 · Most common event earnings

12 positive 2 negative 36 neutral

source · ZBH on sec.gov